Caplin Point Faces 10 USFDA Observations at Gummidipoondi

Caplin Point Laboratories’ subsidiary Caplin Steriles received 10 observations from the USFDA following an unannounced inspection of its Gummidipoondi, Tamil Nadu facility from August 13 to August 21, 2026, covering injectable and ophthalmic manufacturing operations. The observations were issued through a Form 483 and, according to the company, were procedural in nature, with no data-integrity concerns or repeat observations from earlier inspections. Caplin Steriles is working on the observations and will submit its response within the stipulated timeframe. The key monitorable remains the company’s corrective actions and the subsequent regulatory outcome.

Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.